Phase 3 Stomach Cancer Trial, Recruiting NCT06338683 Sponsor: Qinghai Red Cross Hospital Condition: Stomach Cancer
Back to Stomach Cancer

Phase 3 Stomach Cancer Trial, Recruiting

NCT06338683
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard cancer performance scale (scores 0–3)
  • People diagnosed with stage III or IV stomach cancer, esophageal cancer, liver, pancreatic or bile duct cancer, or lung cancer that cannot be removed by surgery or has spread to other parts of the body, confirmed by a tissue or cell sample
  • People who are receiving chemotherapy aimed at managing their cancer rather than curing it, whether as a first or second course of treatment
  • People who are expected to live for at least 3 months
  • People who are able to swallow tablets or capsules by mouth and have no dietary restrictions that would prevent this
  • People who are willing to follow the study schedule, attend follow-up appointments, and sign a consent form agreeing to take part

Who may not be able to join:

  • People whose weight changes are caused by factors other than the cancer itself, such as fluid retention or fluid build-up in the abdomen
  • People who have a mental health condition or who are currently taking antipsychotic or antidepressant medications
  • People with a history of brain or nervous system conditions, such as brain metastases or epilepsy
  • People who regularly take sedative (calming) medications, have been on long-term hormone therapy, have a history of ongoing heavy alcohol use, or are dependent on any substances or medications
  • People who have a medical reason that makes taking the drug olanzapine unsafe for them
  • People who have previously experienced a serious drop in white blood cells caused by a drug called clozapine, as this may increase the risk of a similar reaction with olanzapine
  • People with diabetes that is not well controlled, or with seizures that are not well controlled
  • People who are pregnant or breastfeeding
  • People who are currently taking part in another clinical trial that involves a treatment or intervention, are involved in an observational study, or are still in the follow-up phase of a previous clinical trial
  • People who have any other condition that the trial doctors believe could put them at risk or prevent them from completing the study requirements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Qinghai Red Cross Hospital
Registry
ClinicalTrials.gov
Start date
20 March 2024
Est. completion
20 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Comparing the difference in Median PFS between the two groups

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov